600056 中国医药
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入8,188,780-3.97%35,361,62235,243,41438,824,43137,592,650
减:营业总成本7,879,789-4.25%34,112,38834,019,35637,501,89536,137,940
    其中:营业成本7,319,970-4.02%31,647,84731,459,67134,440,81432,845,786
               财务费用29,443-25.81%110,016211,480112,038138,317
               资产减值损失3-100.17%(150,704)(180,391)(13,539)(280,660)
公允价值变动收益0-100.00%(2,211)127,4679851,922
投资收益7,6150.74%(68,010)(64,072)(15,792)51,001
    其中:对联营企业和合营企业的投资收益19,02217.69%31,36718,73677,04393,219
营业利润312,740-0.07%1,022,988986,5931,672,3341,199,698
利润总额314,3080.45%999,2951,008,1561,640,5561,196,127
减:所得税费用77,168-2.90%324,659274,343398,435307,699
净利润237,1401.58%674,636733,8141,242,120888,428
减:非控股权益54,942-9.74%201,407151,232194,081152,827
股东净利润182,1975.58%473,229582,5821,048,039735,601

市场价值指针
每股收益 (元) *0.1225.55%0.3160.3900.7010.492
每股派息 (元) *----0.0950.1070.2100.148
每股净资产 (元) *8.0340.25%7.9127.9027.7287.230
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容